← Trials/Trial dossier/NCT05598008

Desire PLUS

Completed

Effects of Glucagon-like-Peptide-1 Analogues on Sexuality

The Desire PLUS Study - Effects of Glucagon-like-Peptide-1 Analogues on Sexuality: a Prospective Open-label Study

Lead sponsor

University Hospital, Basel, Switzerland

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•The German short version of the Sexual Desire Inventory (SDI-2) total score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05598008

Org study ID2022-01367; kt22Winzeler

Timeline

Milestones

Study first posted2022-10-28actual

Study start2022-11-25actual

Primary completion2025-10-24actual

Study completion2025-10-24actual

Last update posted2025-12-23actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Sampling methodProbability sample

Study population text

The study population will consist of overweight men and women (BMI ≥ 27 kg/m2), which are seen at the obesity clinic of the University Hospital Basel and who wish to lose weight by lifestyle changes and optionally in combination with liraglutide treatment.

Inclusion criteria

•BMI ≥ 27 kg/m2

•Willingness to lose weight by lifestyle changes only or by lifestyle changes plus GLP-1 analogue treatment as agreed in a routine clinical appointment

•Active sex life (sex with partner or masturbation ≥2x/month)

•Eugonadism:

–Men: morning total testosterone ≥12mmol/l or free testosterone ≥ 0.198 nmol/l if< 50 years old and ≥ 0.163 if > 50 years old

–Women: no primary or secondary amenorrhea (inclusive menopause) *Secondary amenorrhea is defined as "absence of menses for more than three months in women who previously had regular menstrual cycles or six months in women who had irregular menses".

Exclusion criteria

•Diabetes mellitus, HbA1c ≥ 6,5 %

•Previous use of GLP-1 analogues during last 2 months.

•Exogenous testosterone substitution

•Current illicit drug abuse

•Pregnancy

Endpoints (26)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Weight & body composition

Patient-reported / QoL

Other (unclassified)

Cardiometabolic biomarkers

Weight & body composition

7 endpoints

Secondary/protocol endpoint

Change in body weight (kg)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body fat mass (%)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Total fat mass

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in total body water (l)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in extracellular water (%)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

percent change from baseline, improvement

Secondary/protocol endpoint

Change in intracellular water (%)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

percent change from baseline, improvement

Secondary/protocol endpoint

Change in hip/waist ratio

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in visceral fat (%)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Visceral fat, change

percent change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Change in maximum heart rate during spiroergometry

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Heart rate, change

change from baseline, improvement

Patient-reported / QoL

5 endpoints

Primary/protocol endpoint

Change in the German short version of the Sexual Desire Inventory (SDI-2) total score to assess sexual functioning

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in the International Index of Erectile Function (IIEF-5) for men or Female Sexual Function Index (FSFI) for women questionnaire to assess sexual health and erectile function

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in the Patient Health Questionnaire (PHQ) -9 questionnaire to assess mood changes

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in the Patient Health Questionnaire (EQ-5D-5L) questionnaire to assess quality of life

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Change in the Freiburg questionnaire for physical activity (FQPA)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Other clinical outcomes

10 endpoints

Secondary/protocol endpoint

Change in retinal vessel diameters to assess microvascular endothelial functioning

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in semen concentration

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in peak oxygen consumption during spiroergometry to assess physical fitness

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in Testosterone level (nmol/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Androgen, change

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Estradiol level (pmol/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

Androgen, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Sex hormone-binding globulin (SHBG) level (nmol/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in Luteinising hormone (LH) level (U/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Follicle stimulating hormone (LH) level (U/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint

Change in semen motility

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in sperm fragmentation index (percentage of sperm with fragmented DNA)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Change in Oxytocin Level (IU) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Prolactin level (yg/l) (hormone of the reproductive axis)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Basal metabolic rate ((kcal/24h)

Time frame:At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.